DISRUPTIDE
LIVE

Serial Number

99834893

Owner

Rime Therapeutics Inc.

Attorney

Karen K. Won

Filing Date

May 20, 2026

Add to watchlist:

No watchlists yet
View on USPTO

DISRUPTIDE Trademark

Serial Number: 99834893

DISRUPTIDE is a trademark filed by Rime Therapeutics Inc. on May 20, 2026. The trademark is classified under Class 1 (Chemicals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Rime Therapeutics Inc.

3 Place Ville-Marie, Suite 12350
Montréal, QC H3B 0E7 , CA

Entity Type: 03

Trademark Details

Filing Date

May 20, 2026

Registration Date

Not Registered

Goods & Services

chemical preparations and reagents, namely, peptide sequences and peptide probes for use in drug discovery and development; AI-designed peptide probes for use in drug discovery and development; live-cell functional assays and drug screen assays involving engineered peptide probes, for research purposes; engineered peptide probes for live-cell phenotypic screening, intracellular target identification and validation, generation of molecular chemical profiles of function hits at defined target sites, and peptide-based drug discovery and development; genetically-deliverable peptide sequences and peptide probes for preserving peptide conformation, minimizing steric interference, and enhancing peptide intracellular stability

Drug and drug target discovery services; Design, development, and engineering of peptide sequences and peptide probes for use in drug discovery and development; Medical scientific research, analysis, and testing, namely, using engineered peptide probes in live-cell phenotypic screening, intracellular target identification and validation, generation of molecular chemical profiles of function hits at defined target sites, and peptide-based drug discovery and development; Using AI-designed peptide probes to conduct research, testing, and analysis of peptide-target pairs as molecular blueprints for developing small molecule inhibitors; Providing medical scientific information, advisory, and consultancy services in the fields of peptides, peptide-based drug discovery and development, and phenotypic drug screening

Filing History

APPLICATION FILING RECEIPT MAILED
May 20, 2026 MAFR
NEW APPLICATION ENTERED
May 20, 2026 NWAP